| Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label … TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro, ... The Lancet 393 (10183), 1819-1830, 2019 | 2834 | 2019 |
| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1814 | 2020 |
| Planning cancer control in Latin America and the Caribbean PE Goss, BL Lee, T Badovinac-Crnjevic, K Strasser-Weippl, ... The lancet oncology 14 (5), 391-436, 2013 | 624 | 2013 |
| Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE … N Thatcher, FR Hirsch, AV Luft, A Szczesna, TE Ciuleanu, M Dediu, ... The lancet oncology 16 (7), 763-774, 2015 | 540 | 2015 |
| Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study JF Gainor, G Curigliano, DW Kim, DH Lee, B Besse, CS Baik, ... The lancet oncology 22 (7), 959-969, 2021 | 310 | 2021 |
| Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study V Subbiah, MI Hu, LJ Wirth, M Schuler, AS Mansfield, G Curigliano, ... The lancet Diabetes & endocrinology 9 (8), 491-501, 2021 | 248 | 2021 |
| Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS)≥ 1%: open-label … G Lopes, YL Wu, I Kudaba, D Kowalski, BC Cho, G Castro, ... Journal of Clinical Oncology 36 (18_suppl), LBA4-LBA4, 2018 | 248 | 2018 |
| Early detection for colorectal cancer: ASCO resource-stratified guideline G Lopes, MC Stern, S Temin, AI Sharara, A Cervantes, A Costas-Chavarri, ... Journal of global oncology 5, 1-22, 2019 | 232 | 2019 |
| Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024 … K Nosaki, H Saka, Y Hosomi, P Baas, G de Castro Jr, M Reck, YL Wu, ... Lung Cancer 135, 188-195, 2019 | 229 | 2019 |
| PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data PN Aguiar Jr, RA De Mello, P Hall, H Tadokoro, G Lima Lopes Immunotherapy 9 (6), 499-506, 2017 | 196 | 2017 |
| Progress and remaining challenges for cancer control in Latin America and the Caribbean K Strasser-Weippl, Y Chavarri-Guerra, C Villarreal-Garza, BL Bychkovsky, ... The lancet oncology 16 (14), 1405-1438, 2015 | 196 | 2015 |
| Global health equity: cancer care outcome disparities in high-, middle-, and low-income countries JA De Souza, B Hunt, FC Asirwa, C Adebamowo, G Lopes Journal of Clinical Oncology 34 (1), 6, 2016 | 195 | 2016 |
| How uncommon are isolated lung metastases in colorectal cancer? A review from database of 754 patients over 4 years KK Tan, G de Lima Lopes Jr, R Sim Journal of gastrointestinal surgery 13 (4), 642-648, 2009 | 174 | 2009 |
| Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19 MA Thompson, JP Henderson, PK Shah, SM Rubinstein, MJ Joyner, ... JAMA oncology 7 (8), 1167-1175, 2021 | 169 | 2021 |
| The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis PN Aguiar Jr, IL Santoro, H Tadokoro, G de Lima Lopes, BA Filardi, ... Immunotherapy 8 (4), 479-488, 2016 | 168 | 2016 |
| Large vessel involvement in ANCA-associated vasculitides: report of a case and review of the literature JA Chirinos, LJ Tamariz, G Lopes, F Del Carpio, X Zhang, C Milikowski, ... Clinical rheumatology 23, 152-159, 2004 | 143 | 2004 |
| Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and Cancer Consortium (CCC19) cohort study DR Rivera, S Peters, OA Panagiotou, DP Shah, NM Kuderer, CY Hsu, ... Cancer discovery 10 (10), 1514-1527, 2020 | 141 | 2020 |
| A phase II trial of nab-paclitaxel as second-line therapy in patients with advanced pancreatic cancer PJ Hosein, G de Lima Lopes Jr, VH Pastorini, C Gomez, J Macintyre, ... American Journal of Clinical Oncology, 2012 | 136 | 2012 |
| Lung cancer in Brazil LH Araujo, C Baldotto, G Castro Jr, A Katz, CG Ferreira, C Mathias, ... Jornal Brasileiro de Pneumologia 44, 55-64, 2018 | 129 | 2018 |
| Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-Fusion+ non small cell lung cancer JF Gainor, DH Lee, G Curigliano, RC Doebele, DW Kim, CS Baik J Clin Oncol 37 (15 suppl), 9008, 2019 | 128 | 2019 |
Ben HaalandUniversity of UtahVerified email at hsc.utah.edu
